Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
178.27
-0.61 (-0.34%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Glaukos Employees
Glaukos had 1,094 employees as of December 31, 2025. The number of employees increased by 99 or 9.95% compared to the previous year. That makes Glaukos the 14,208th largest employer in the world and 2,122nd in the United States.
Employees
1,094
Change (1Y)
99
Growth (1Y)
9.95%
Revenue / Employee
$560,182
Profits / Employee
-$171,890
Market Cap
10.51B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,094 | 99 | 9.95% |
| Dec 31, 2024 | 995 | 88 | 9.70% |
| Dec 31, 2023 | 907 | 124 | 15.84% |
| Dec 31, 2022 | 783 | 56 | 7.70% |
| Dec 31, 2021 | 727 | 74 | 11.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| STERIS | 17,937 |
| Zimmer Biomet Holdings | 17,000 |
| Smith & Nephew | 16,988 |
| Bruker | 11,085 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
| Globus Medical | 6,000 |
| Insulet | 5,400 |
GKOS News
- 13 days ago - Glaukos price target raised to $190 from $185 at Mizuho - TheFly
- 14 days ago - Glaukos price target raised to $205 from $202 at BTIG - TheFly
- 17 days ago - Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint - TheFly
- 17 days ago - Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - Business Wire
- 18 days ago - Glaukos falls -7.4% - TheFly
- 18 days ago - Glaukos announces exclusive license agreement with RevOpsis for RO-104 - TheFly
- 18 days ago - Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - Business Wire
- 19 days ago - Glaukos says late-stage eye disease treatment shows lasting benefits after single dose - Reuters